688488 艾迪药业
已收盘 11-04 15:00:00
资讯
新帖
简况
艾迪药业（688488）11月3日主力资金净买入1894.19万元
证券之星 · 11-04 09:12
艾迪药业（688488）11月3日主力资金净买入1894.19万元
艾迪药业(688488.SH)拟1000万元至2000万元回购公司股份
智通财经 · 11-03 17:01
艾迪药业(688488.SH)拟1000万元至2000万元回购公司股份
艾迪药业（688488）11月2日主力资金净买入1106.53万元
证券之星 · 11-03 08:40
艾迪药业（688488）11月2日主力资金净买入1106.53万元
股市必读：艾迪药业三季报 - 第三季度单季净利润同比增长80.52%
证券之星 · 11-02 05:51
股市必读：艾迪药业三季报 - 第三季度单季净利润同比增长80.52%
艾迪药业(688488)9月30日股东户数1.25万户，较上期增加2.36%
证券之星 · 10-30
艾迪药业(688488)9月30日股东户数1.25万户，较上期增加2.36%
艾迪药业前三季度利润扭亏 HIV产品仍是核心变量
蓝鲸财经 · 10-30
艾迪药业前三季度利润扭亏 HIV产品仍是核心变量
图解艾迪药业三季报：第三季度单季净利润同比增长80.52%
证券之星 · 10-30
图解艾迪药业三季报：第三季度单季净利润同比增长80.52%
艾迪药业（688488）披露2026年第三季度报告，10月29日股价下跌3.95%
证券之星 · 10-29
艾迪药业（688488）披露2026年第三季度报告，10月29日股价下跌3.95%
10月27日艾迪药业跌13.09%，东方红医疗升级股票发起A基金重仓该股
证券之星 · 10-27
10月27日艾迪药业跌13.09%，东方红医疗升级股票发起A基金重仓该股
股市必读：艾迪药业新发布《艾迪药业关于ADC118片获得药物临床试验批准通知书的自愿性披露公告》
证券之星 · 10-19
股市必读：艾迪药业新发布《艾迪药业关于ADC118片获得药物临床试验批准通知书的自愿性披露公告》
艾迪药业（688488）10月16日主力资金净买入331.89万元
证券之星 · 10-17
艾迪药业（688488）10月16日主力资金净买入331.89万元
艾迪药业：ADC118片获药物临床试验批准通知书
格隆汇 · 10-15
艾迪药业：ADC118片获药物临床试验批准通知书
艾迪药业（688488）10月14日主力资金净卖出378.06万元
证券之星 · 10-15
艾迪药业（688488）10月14日主力资金净卖出378.06万元
艾迪药业（688488）10月12日主力资金净卖出417.68万元
证券之星 · 10-13
艾迪药业（688488）10月12日主力资金净卖出417.68万元
10月8日艾迪药业跌7.52%，华商科创创业精选混合A基金重仓该股
证券之星 · 10-08
10月8日艾迪药业跌7.52%，华商科创创业精选混合A基金重仓该股
艾迪药业（688488）9月29日主力资金净买入1399.77万元
证券之星 · 09-30
艾迪药业（688488）9月29日主力资金净买入1399.77万元
9月21日艾迪药业涨8.21%，华商科创创业精选混合A基金重仓该股
证券之星 · 09-21
9月21日艾迪药业涨8.21%，华商科创创业精选混合A基金重仓该股
连亏5年股艾迪药业调降定增募资金额 为兴全基金重仓股
中金财经 · 09-18
连亏5年股艾迪药业调降定增募资金额 为兴全基金重仓股
艾迪药业最新公告：拟定增募资不超9.45亿元用于新型HIV整合酶抑制剂全球临床开发项目等
证券之星 · 09-17
艾迪药业最新公告：拟定增募资不超9.45亿元用于新型HIV整合酶抑制剂全球临床开发项目等
江苏艾迪药业调整定增方案：拟募资上限降至9.45亿元，较此前公布的13亿元有所缩减
美股速递 · 09-17
江苏艾迪药业调整定增方案：拟募资上限降至9.45亿元，较此前公布的13亿元有所缩减
加载更多
公司概况
公司名称：
江苏艾迪药业集团股份有限公司
所属行业：
其他制造业
上市日期：
2020-07-20
主营业务：
江苏艾迪药业集团股份有限公司的主营业务是抗HIV药物和人源蛋白领域药物的研发、生产及销售。公司的主要产品是艾诺韦林片、艾诺米替片、注射用尿激酶。公司是国家级高新技术企业。
发行价格：
13.99
{"stockData":{"symbol":"688488","market":"SH","secType":"STK","nameCN":"艾迪药业","latestPrice":11.69,"timestamp":1793775600000,"preClose":11.09,"halted":0,"volume":15001192,"delay":0,"changeRate":0.0541,"floatShares":421000000,"shares":421000000,"eps":0.017,"marketStatus":"已收盘","change":0.6,"latestTime":"11-04 15:00:00","open":11.15,"high":11.86,"low":11.03,"amount":173000000,"amplitude":0.0748,"askPrice":11.7,"askSize":107,"bidPrice":11.69,"bidSize":98,"shortable":0,"etf":0,"ttmEps":0.017,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793842200000},"marketStatusCode":5,"adr":0,"adjPreClose":11.09,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793755800000,1793763000000],[1793768400000,1793775600000]],"highLimit":12.2,"lowLimit":9.98,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":420782808,"isCdr":false,"pbRate":5.38,"roa":"--","peRate":687.647059,"roe":"2.12%","epsLYR":-0.05,"committee":-0.085487,"marketValue":4919000000,"turnoverRate":0.0357,"status":0,"afterMarket":{"amount":4676,"volume":400,"close":11.69,"buyVolume":25500,"sellVolume":0,"time":1793777637746,"indexStatus":"已收盘 11-04 15:30:00","preClose":11.09},"floatMarketCap":4919000000},"requestUrl":"/m/hq/s/688488","defaultTab":"news","newsList":[{"id":"2680570428","title":"艾迪药业（688488）11月3日主力资金净买入1894.19万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680570428","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680570428?lang=zh_cn&edition=full","pubTime":"2026-11-04 09:12","pubTimestamp":1793754731,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月3日收盘，艾迪药业报收于11.09元，下跌5.54%，换手率2.83%，成交量11.89万手，成交额1.34亿元。近5日资金流向一览见下表：艾迪药业融资融券信息显示，融资方面，当日融资买入1129.09万元，融资偿还1132.05万元，融资净偿还2.96万元。艾迪药业主营业务：抗HIV药物和人源蛋白领域药物的研发、生产及销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400011396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680174662","title":"艾迪药业(688488.SH)拟1000万元至2000万元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2680174662","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680174662?lang=zh_cn&edition=full","pubTime":"2026-11-03 17:01","pubTimestamp":1793696509,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾迪药业(688488.SH)发布公告，公司拟通过上海证券交易所交易系统以集中竞价交易方式回购公司已发行的部分人民币普通股(A股)股票，并在未来适宜时机用于员工持股计划或者股权激励。回购股份金额不低于人民币1,000万元(含)，不超过人民币2,000万元(含)，回购股份价格不超过人民币22.39元/股(含)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517767.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680276792","title":"艾迪药业（688488）11月2日主力资金净买入1106.53万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680276792","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680276792?lang=zh_cn&edition=full","pubTime":"2026-11-03 08:40","pubTimestamp":1793666440,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月2日收盘，艾迪药业报收于11.74元，下跌1.59%，换手率2.89%，成交量12.17万手，成交额1.43亿元。近5日资金流向一览见下表：艾迪药业融资融券信息显示，融资方面，当日融资买入1030.02万元，融资偿还724.46万元，融资净买入305.56万元。艾迪药业主营业务：抗HIV药物和人源蛋白领域药物的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300010556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680788861","title":"股市必读：艾迪药业三季报 - 第三季度单季净利润同比增长80.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680788861","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680788861?lang=zh_cn&edition=full","pubTime":"2026-11-02 05:51","pubTimestamp":1793569876,"startTime":"0","endTime":"0","summary":"业绩披露要点：2026年前三季度归母净利润1981.13万元，同比上升389.62%；第三季度单季度归母净利润为-312.28万元，同比上升80.52%。公司公告汇总艾迪药业2026年第三季度报告2026年第三季度营业收入1.84亿元，同比下降3.03%；年初至报告期末营业收入5.50亿元，同比下降0.43%。年初至报告期末经营活动现金流量净额7766.41万元，同比增长182.53%；研发投入合计8619.88万元，同比增长25.99%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200001620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679218079","title":"艾迪药业(688488)9月30日股东户数1.25万户，较上期增加2.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679218079","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679218079?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:13","pubTimestamp":1793358809,"startTime":"0","endTime":"0","summary":"证券之星消息，近日艾迪药业披露，截至2026年9月30日公司股东户数为1.25万户，较6月30日增加287.0户，增幅为2.36%。在生物制品行业个股中，艾迪药业股东户数低于行业平均水平，截至9月30日，生物制品行业平均股东户数为3.67万户。从股价来看，2026年6月30日至2026年9月30日，艾迪药业区间涨幅为29.42%，在此期间股东户数增加287.0户，增幅为2.36%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000046768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679371298","title":"艾迪药业前三季度利润扭亏 HIV产品仍是核心变量","url":"https://stock-news.laohu8.com/highlight/detail?id=2679371298","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679371298?lang=zh_cn&edition=full","pubTime":"2026-10-30 16:24","pubTimestamp":1793348664,"startTime":"0","endTime":"0","summary":"艾迪药业主要聚焦抗HIV药物和人源蛋白两大领域。抗HIV创新药则是艾迪药业业绩增长的核心引擎。2026年前三季度，HIV领域药品收入约2.78亿元、同比增长31.73%，其中第三季度为9762万元，延续了上半年的增长势头。作为国内抗HIV领域头部企业之一，艾迪药业目前已有4款抗HIV药物获批上市。在预防领域，艾迪药业前瞻性布局HIV暴露前预防长效药物。总体来看，艾迪药业HIV商业化已初步跑通，公司正由“投入期”步入“兑现期”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/2519768","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679238221","title":"图解艾迪药业三季报：第三季度单季净利润同比增长80.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679238221","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679238221?lang=zh_cn&edition=full","pubTime":"2026-10-30 02:57","pubTimestamp":1793300264,"startTime":"0","endTime":"0","summary":"证券之星消息，艾迪药业2026年三季报显示，前三季度公司主营收入5.5亿元，同比下降0.43%；归母净利润1981.13万元，同比上升389.62%；扣非净利润2450.68万元，同比上升231.67%；其中2026年第三季度，公司单季度主营收入1.84亿元，同比下降3.03%；单季度归母净利润-312.28万元，同比上升80.52%；单季度扣非净利润405.01万元，同比上升130.0%；负债率48.96%，投资收益-33.27万元，财务费用1230.12万元，毛利率66.06%。财报数据概要请见下图:本文数据来源于艾迪药业2026年三季报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000005616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679828675","title":"艾迪药业（688488）披露2026年第三季度报告，10月29日股价下跌3.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679828675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679828675?lang=zh_cn&edition=full","pubTime":"2026-10-29 22:22","pubTimestamp":1793283732,"startTime":"0","endTime":"0","summary":"近日，江苏艾迪药业集团股份有限公司披露《2026年第三季度报告》。报告显示，本报告期营业收入为184,154,976.29元，较上年同期下降3.03%；年初至报告期末营业收入为550,009,734.54元，较上年同期下降0.43%。本报告期利润总额为-2,622,537.88元；年初至报告期末利润总额为34,409,366.31元，同比增长29.25%。归属于上市公司股东的净利润本报告期为-3,122,803.51元；年初至报告期末为19,811,270.15元。研发投入合计本报告期为26,722,491.55元，同比增长11.22%；年初至报告期末为86,198,784.63元，同比增长25.99%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900063237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678124978","title":"10月27日艾迪药业跌13.09%，东方红医疗升级股票发起A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678124978","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678124978?lang=zh_cn&edition=full","pubTime":"2026-10-27 16:53","pubTimestamp":1793091239,"startTime":"0","endTime":"0","summary":"证券之星消息，10月27日艾迪药业跌13.09%创60日新低，收盘报12.35元，换手率3.96%，成交量16.65万手，成交额2.15亿元。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共11家，其中持有数量最多的公募基金为东方红资产管理的东方红医疗升级股票发起A。东方红医疗升级股票发起A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700031565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676057359","title":"股市必读：艾迪药业新发布《艾迪药业关于ADC118片获得药物临床试验批准通知书的自愿性披露公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676057359","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676057359?lang=zh_cn&edition=full","pubTime":"2026-10-19 02:55","pubTimestamp":1792349709,"startTime":"0","endTime":"0","summary":"公司公告汇总艾迪药业关于ADC118片获得药物临床试验批准通知书的自愿性披露公告江苏艾迪药业集团股份有限公司及全资子公司收到国家药监局核准签发的《药物临床试验批准通知书》，同意抗艾滋病领域在研1类新药ADC118片开展III期临床试验。艾迪药业关于拟注销全资子公司的公告江苏艾迪药业集团股份有限公司于2026年10月16日召开第三届董事会第二十次会议，审议通过注销全资子公司南京安赛莱医药科技有限公司的议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900000886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676751061","title":"艾迪药业（688488）10月16日主力资金净买入331.89万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2676751061","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676751061?lang=zh_cn&edition=full","pubTime":"2026-10-17 08:19","pubTimestamp":1792196388,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月16日收盘，艾迪药业报收于13.9元，上涨2.66%，换手率1.78%，成交量7.51万手，成交额1.06亿元。近5日资金流向一览见下表：艾迪药业融资融券信息显示，融资方面，当日融资买入553.23万元，融资偿还1140.74万元，融资净偿还587.5万元。艾迪药业主营业务：抗HIV药物和人源蛋白领域药物的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101700005726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675854835","title":"艾迪药业：ADC118片获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2675854835","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675854835?lang=zh_cn&edition=full","pubTime":"2026-10-15 18:35","pubTimestamp":1792060558,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675375793","title":"艾迪药业（688488）10月14日主力资金净卖出378.06万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675375793","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675375793?lang=zh_cn&edition=full","pubTime":"2026-10-15 08:33","pubTimestamp":1792024386,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月14日收盘，艾迪药业报收于13.95元，下跌4.26%，换手率1.74%，成交量7.3万手，成交额1.03亿元。近5日资金流向一览见下表：艾迪药业融资融券信息显示，融资方面，当日融资买入649.32万元，融资偿还667.23万元，融资净偿还17.91万元。艾迪药业主营业务：抗HIV药物和人源蛋白领域药物的研发、生产及销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500007209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675386125","title":"艾迪药业（688488）10月12日主力资金净卖出417.68万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675386125","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675386125?lang=zh_cn&edition=full","pubTime":"2026-10-13 08:33","pubTimestamp":1791851637,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月12日收盘，艾迪药业报收于15.0元，下跌4.76%，换手率1.37%，成交量5.76万手，成交额8779.66万元。近5日资金流向一览见下表：艾迪药业融资融券信息显示，融资方面，当日融资买入748.12万元，融资偿还586.98万元，融资净买入161.14万元。艾迪药业主营业务：抗HIV药物和人源蛋白领域药物的研发、生产及销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101300007214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673027599","title":"10月8日艾迪药业跌7.52%，华商科创创业精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2673027599","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673027599?lang=zh_cn&edition=full","pubTime":"2026-10-08 16:40","pubTimestamp":1791448854,"startTime":"0","endTime":"0","summary":"证券之星消息，10月8日艾迪药业跌7.52%，收盘报15.38元，换手率2.28%，成交量9.6万手，成交额1.51亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为华商基金的华商科创创业精选混合A。华商科创创业精选混合A目前规模为1.96亿元，最新净值1.8269，较上一交易日下跌2.18%。华商科创创业精选混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800021334.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262","159781"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671918225","title":"艾迪药业（688488）9月29日主力资金净买入1399.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671918225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671918225?lang=zh_cn&edition=full","pubTime":"2026-09-30 08:23","pubTimestamp":1790727806,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月29日收盘，艾迪药业报收于16.12元，上涨2.74%，换手率1.83%，成交量7.71万手，成交额1.25亿元。近5日资金流向一览见下表：艾迪药业融资融券信息显示，融资方面，当日融资买入1049.12万元，融资偿还893.57万元，融资净买入155.55万元。艾迪药业主营业务：抗HIV药物和人源蛋白领域药物的研发、生产及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000006581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669596041","title":"9月21日艾迪药业涨8.21%，华商科创创业精选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669596041","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669596041?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:42","pubTimestamp":1789980165,"startTime":"0","endTime":"0","summary":"证券之星消息，9月21日艾迪药业涨8.21%，收盘报16.6元，换手率3.37%，成交量14.18万手，成交额2.31亿元。重仓艾迪药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为华商基金的华商科创创业精选混合A。华商科创创业精选混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159781","688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668943675","title":"连亏5年股艾迪药业调降定增募资金额 为兴全基金重仓股","url":"https://stock-news.laohu8.com/highlight/detail?id=2668943675","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668943675?lang=zh_cn&edition=full","pubTime":"2026-09-18 14:52","pubTimestamp":1789714326,"startTime":"0","endTime":"0","summary":"中国经济网北京9月18日讯 艾迪药业 昨晚发布关于2026年度向特定对象发行A股股票方案及预案修订情况说明的公告。 公司对本次向特定对象发行A股股票的募投项目及募集资金金额相关事项以及公司实际控制人傅和亮作为发行对象之一的认购方式进行了调整，调整后的募投项目及募集资金总额不超过94,498.32万元(含本数)，扣除发行费用后净额拟用于新型HIV整合酶抑制剂全球临床开发项目、年产5亿片抗艾滋病固体制剂药物项目、补充流动资金。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/18/20260918168954.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/18/20260918168954.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260918/32374315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668596917","title":"艾迪药业最新公告：拟定增募资不超9.45亿元用于新型HIV整合酶抑制剂全球临床开发项目等","url":"https://stock-news.laohu8.com/highlight/detail?id=2668596917","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668596917?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:00","pubTimestamp":1789642834,"startTime":"0","endTime":"0","summary":"艾迪药业(688488.SH)公告称，公司董事会审议通过2026年度向特定对象发行A股股票方案，拟募资总额不超过9.45亿元，用于新型HIV整合酶抑制剂全球临床开发项目、年产5亿片抗艾滋病固体制剂药物项目及补充流动资金。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700030885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688488","BK0262"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187101379","title":"江苏艾迪药业调整定增方案：拟募资上限降至9.45亿元，较此前公布的13亿元有所缩减","url":"https://stock-news.laohu8.com/highlight/detail?id=1187101379","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187101379?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:00","pubTimestamp":1789642811,"startTime":"0","endTime":"0","summary":"江苏艾迪药业宣布，计划通过非公开发行股票方式募集资金，募资总额上限调整为9.45亿元。这一数字较该公司早前披露的13亿元募资计划，出现了明显下调。从原先的13亿元目标收缩至9.45亿元，降幅约达27.3%，显示出企业根据市场环境及自身资金需求状况，对资本运作方案作出的重新规划与优化。未来，艾迪药业将如何利用这笔资金布局核心业务，以及新方案能否顺利获得监管批准并落地实施，无疑将成为投资者关注的焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0262","688488"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793810430426,"stockEarnings":[{"period":"1week","weight":-0.0766},{"period":"1month","weight":-0.2971},{"period":"3month","weight":-0.2766},{"period":"6month","weight":-0.3196},{"period":"1year","weight":-0.2133},{"period":"ytd","weight":-0.2841}],"compareEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":-0.0406},{"period":"3month","weight":-0.0549},{"period":"6month","weight":-0.1181},{"period":"1year","weight":-0.0692},{"period":"ytd","weight":-0.0712}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏艾迪药业集团股份有限公司","boardCode":"AI0041","boardName":"其他制造业","stockholders":"12455人(较上一季度增加2.36%)","perCapita":"33784股","listingDate":"2020-07-20","address":"江苏省扬州市邗江区新甘泉西路69号","registeredCapital":"42078万元","survey":" 江苏艾迪药业集团股份有限公司的主营业务是抗HIV药物和人源蛋白领域药物的研发、生产及销售。公司的主要产品是艾诺韦林片、艾诺米替片、注射用尿激酶。公司是国家级高新技术企业。","listedPrice":13.99},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾迪药业(688488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾迪药业,688488,艾迪药业股票,艾迪药业股票老虎,艾迪药业股票老虎国际,艾迪药业行情,艾迪药业股票行情,艾迪药业股价,艾迪药业股市,艾迪药业股票价格,艾迪药业股票交易,艾迪药业股票购买,艾迪药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾迪药业(688488)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾迪药业(688488)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}